The AACR Annual Meeting 2014 took place April 5-9 in San Diego, California.

Leukemic breast tumors may cause resistance in AML, ALL

Dr Cunningham

One woman’s curiosity and self-described “aggressive” approach to research have led to some unexpected discoveries about acute leukemias. Isabel Cunningham, MD, of Columbia University in New York, has found evidence to suggest that treatment resistance in leukemia patients may sometimes result from an interaction between leukemic cells and the breast. She discovered that... [Read Article]

Team identifies potential treatment for FLT3-ITD AML

DNA coiled around histones
Credit: Eric Smith

Researchers have presented evidence to support the use of a BET protein antagonist in FLT3-ITD-mutated acute myeloid leukemia (AML). The group’s experiments showed the antagonist, JQ1, was active against FLT3-ITD-expressing AML cells in vitro and in vivo. The agent also demonstrated synergy with the tyrosine kinase inhibitor... [Read Article]

Molecule shows preclinical activity in leukemias, lymphomas

AML cells in the bone marrow

A small molecule that has previously proven effective against solid tumors exhibits activity against leukemias and lymphomas, preclinical research suggests. The molecule, OR-253, showed antiproliferative activity in a range of leukemia and lymphoma cell lines, induced apoptosis in acute myeloid leukemia (AML) in vitro, and demonstrated synergy with chemotherapeutic... [Read Article]

Compound targets mutated DLBCL, WM cells

Micrograph showing DLBCL

A Toll-like receptor (TLR) antagonist can target B-cell lymphoma cells harboring the MYD88 L265P mutation, preclinical research suggests. The compound, IMO-8400, decreased the viability of mutated diffuse large B-cell lymphoma (DLBCL) cells and Waldenström’s macroglobulinemia (WM) cells in vitro. IMO-8400 also decreased tumor growth and prolonged survival in mice with MYD88 L265P-positive... [Read Article]

Reovirus shows synergy with agents used to treat MM

Poster session at AACR 2014
Credit: AACR/Todd Buchanan

Reovirus can induce cell death in a range of multiple myeloma (MM) cell lines, and it is synergistic with drugs used to treat MM, according to research presented at the AACR Annual Meeting 2014. Six of the 7 MM cell lines tested were at least moderately... [Read Article]

Group describes mechanism of resistance in CLL

AACR Annual Meeting 2014

Preclinical research has revealed a mechanism of rituximab resistance in chronic lymphocytic leukemia (CLL), as well as a possible new treatment approach. The study suggests the TNF-family member BAFF contributes to CLL cells’ resistance to direct and rituximab-induced natural killer (NK) cell reactivity. However, the BAFF-specific antibody belimumab can overcome this... [Read Article]

Dual kinase inhibitor targets heterogeneity in AML

Lab mouse

A dual kinase inhibitor shows potential for treating the heterogeneous acute myeloid leukemia (AML) population, researchers say. The inhibitor, SEL24-B489, targets both PIM and FLT3 mutants. In experiments, it exhibited more consistent activity across AML cell lines than inhibitors directed only at PIM or FLT3. SEL24-B489 also demonstrated synergistic activity with cytarabine,... [Read Article]

Heparanase regulates response to chemo in MM, team says

Attendees at AACR 2014
AACR/Todd Buchanan

Experiments conducted in the lab and the clinic suggest the enzyme heparanase enhances resistance to chemotherapy in multiple myeloma (MM). Researchers first found that heparanase expression is highly elevated in MM patients after chemotherapy. The team then used MM cell lines to investigate the mechanism behind this phenomenon.... [Read Article]

Molecule can increase Hb in anemic cancer patients

Red blood cells

Results of a pilot study suggest an experimental molecule can increase hemoglobin levels in patients with hematologic malignancies who are suffering from anemia. The molecule, lexaptepid pegol (NOX-H94), is a pegylated L-stereoisomer RNA aptamer that binds and neutralizes hepcidin. In this phase 2 study, 5 of 12 patients who received lexaptepid pegol... [Read Article]

Combo may overcome bortezomib resistance in MCL

Poster session at AACR 2014
AACR/Todd Buchanan

Preclinical research suggests that combining a BET inhibitor with lenalidomide may overcome resistance to bortezomib in mantle cell lymphoma (MCL). Experiments in MCL cell lines and mouse models of the disease showed that lenalidomide alone is active in bortezomib-resistant cells and tumors. But the anticancer effects are... [Read Article]